 Karl Bayer
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 73 | 2026 | 196 | 21.090 |
Why?
| | Long-Term Potentiation | 25 | 2026 | 200 | 8.400 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 27 | 2026 | 228 | 6.640 |
Why?
| | Hippocampus | 33 | 2025 | 967 | 4.010 |
Why?
| | Long-Term Synaptic Depression | 9 | 2023 | 51 | 3.280 |
Why?
| | Synapses | 17 | 2024 | 439 | 3.060 |
Why?
| | Phosphorylation | 40 | 2026 | 1733 | 2.890 |
Why?
| | Memory | 6 | 2024 | 296 | 2.490 |
Why?
| | Calcium | 21 | 2024 | 1184 | 2.420 |
Why?
| | Neuronal Plasticity | 9 | 2025 | 309 | 1.890 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 14 | 2011 | 168 | 1.870 |
Why?
| | Neurons | 23 | 2025 | 1642 | 1.850 |
Why?
| | Death-Associated Protein Kinases | 3 | 2021 | 10 | 1.830 |
Why?
| | Glutamic Acid | 9 | 2023 | 251 | 1.710 |
Why?
| | Neuroprotective Agents | 5 | 2025 | 143 | 1.520 |
Why?
| | Brain Ischemia | 3 | 2025 | 358 | 1.480 |
Why?
| | Calmodulin | 10 | 2019 | 70 | 1.360 |
Why?
| | Animals | 67 | 2026 | 38109 | 1.260 |
Why?
| | Rats | 34 | 2025 | 5614 | 1.220 |
Why?
| | Protein Binding | 20 | 2026 | 2276 | 1.200 |
Why?
| | Heart Arrest | 3 | 2021 | 407 | 1.060 |
Why?
| | Mutation | 10 | 2026 | 4099 | 1.000 |
Why?
| | Dendritic Spines | 4 | 2024 | 69 | 1.000 |
Why?
| | Amyloid beta-Peptides | 3 | 2025 | 241 | 0.980 |
Why?
| | Cell Death | 5 | 2021 | 383 | 0.940 |
Why?
| | Ischemia | 3 | 2020 | 421 | 0.910 |
Why?
| | HEK293 Cells | 9 | 2025 | 744 | 0.900 |
Why?
| | Cyclopentanes | 1 | 2025 | 20 | 0.890 |
Why?
| | CA1 Region, Hippocampal | 2 | 2022 | 51 | 0.840 |
Why?
| | Receptors, Metabotropic Glutamate | 2 | 2022 | 37 | 0.820 |
Why?
| | Protein Kinase Inhibitors | 9 | 2025 | 970 | 0.780 |
Why?
| | Learning | 2 | 2024 | 452 | 0.780 |
Why?
| | Rats, Sprague-Dawley | 17 | 2020 | 2540 | 0.750 |
Why?
| | Amino Acid Sequence | 14 | 2019 | 2157 | 0.750 |
Why?
| | Mice | 23 | 2025 | 18365 | 0.710 |
Why?
| | Protein Processing, Post-Translational | 4 | 2019 | 477 | 0.690 |
Why?
| | Alzheimer Disease | 3 | 2025 | 622 | 0.680 |
Why?
| | Electrophysiological Phenomena | 1 | 2021 | 60 | 0.660 |
Why?
| | Alternative Splicing | 5 | 2006 | 249 | 0.630 |
Why?
| | N-Methylaspartate | 9 | 2022 | 43 | 0.620 |
Why?
| | Nitric Oxide | 2 | 2014 | 897 | 0.600 |
Why?
| | Holoenzymes | 2 | 2021 | 25 | 0.590 |
Why?
| | Disks Large Homolog 4 Protein | 1 | 2019 | 18 | 0.590 |
Why?
| | Cerebral Cortex | 3 | 2021 | 465 | 0.580 |
Why?
| | Post-Synaptic Density | 6 | 2016 | 12 | 0.560 |
Why?
| | Brain | 7 | 2019 | 2941 | 0.560 |
Why?
| | Peptides | 6 | 2023 | 998 | 0.550 |
Why?
| | Cells, Cultured | 13 | 2021 | 4155 | 0.540 |
Why?
| | Lipoylation | 1 | 2017 | 17 | 0.540 |
Why?
| | Green Fluorescent Proteins | 6 | 2025 | 405 | 0.520 |
Why?
| | Molecular Sequence Data | 12 | 2014 | 2931 | 0.520 |
Why?
| | Adenosine Diphosphate | 3 | 2015 | 84 | 0.510 |
Why?
| | Protein Transport | 8 | 2019 | 441 | 0.510 |
Why?
| | Synaptic Transmission | 3 | 2019 | 290 | 0.510 |
Why?
| | A Kinase Anchor Proteins | 1 | 2017 | 70 | 0.510 |
Why?
| | Excitatory Amino Acid Agonists | 3 | 2014 | 42 | 0.490 |
Why?
| | Spine | 1 | 2017 | 182 | 0.470 |
Why?
| | Adenosine Triphosphate | 4 | 2013 | 498 | 0.470 |
Why?
| | Microscopy, Fluorescence | 3 | 2015 | 418 | 0.440 |
Why?
| | Second Messenger Systems | 1 | 2014 | 31 | 0.420 |
Why?
| | Models, Molecular | 8 | 2019 | 1619 | 0.420 |
Why?
| | Mice, Inbred C57BL | 9 | 2025 | 5997 | 0.400 |
Why?
| | Carrier Proteins | 6 | 2016 | 737 | 0.400 |
Why?
| | Protein Conformation | 7 | 2021 | 946 | 0.400 |
Why?
| | Protein Interaction Mapping | 2 | 2019 | 105 | 0.370 |
Why?
| | Membrane Proteins | 1 | 2019 | 1167 | 0.370 |
Why?
| | Actin Cytoskeleton | 3 | 2016 | 103 | 0.370 |
Why?
| | Humans | 33 | 2026 | 144957 | 0.350 |
Why?
| | Protein Isoforms | 4 | 2018 | 402 | 0.350 |
Why?
| | Autophagy | 1 | 2014 | 286 | 0.340 |
Why?
| | Nucleotides | 1 | 2011 | 128 | 0.330 |
Why?
| | Drug Design | 1 | 2011 | 173 | 0.320 |
Why?
| | Actins | 4 | 2016 | 425 | 0.320 |
Why?
| | Nerve Tissue Proteins | 4 | 2019 | 592 | 0.320 |
Why?
| | Transfection | 5 | 2017 | 940 | 0.320 |
Why?
| | Receptors, AMPA | 3 | 2024 | 147 | 0.310 |
Why?
| | Substrate Specificity | 4 | 2014 | 392 | 0.310 |
Why?
| | Protein Domains | 4 | 2019 | 313 | 0.310 |
Why?
| | Peptide Fragments | 4 | 2018 | 699 | 0.300 |
Why?
| | Cell Line | 8 | 2011 | 2882 | 0.290 |
Why?
| | Gene Expression Regulation, Enzymologic | 4 | 2018 | 269 | 0.290 |
Why?
| | Isoenzymes | 5 | 2014 | 299 | 0.290 |
Why?
| | Mice, Knockout | 3 | 2021 | 3125 | 0.280 |
Why?
| | Neuroprotection | 2 | 2020 | 46 | 0.270 |
Why?
| | Benzylamines | 5 | 2013 | 43 | 0.250 |
Why?
| | Cell Nucleus | 3 | 2012 | 619 | 0.240 |
Why?
| | Spinal Cord | 2 | 2025 | 382 | 0.220 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2016 | 117 | 0.220 |
Why?
| | Spinal Cord Ischemia | 1 | 2025 | 60 | 0.220 |
Why?
| | Enzyme Activation | 6 | 2017 | 768 | 0.220 |
Why?
| | Ionomycin | 2 | 2019 | 22 | 0.210 |
Why?
| | Protein Kinases | 1 | 2006 | 315 | 0.210 |
Why?
| | Biological Products | 1 | 2007 | 252 | 0.210 |
Why?
| | Binding Sites | 4 | 2014 | 1331 | 0.210 |
Why?
| | Signal Transduction | 7 | 2014 | 5233 | 0.200 |
Why?
| | Male | 18 | 2025 | 72406 | 0.200 |
Why?
| | D-Aspartic Acid | 1 | 2023 | 2 | 0.200 |
Why?
| | Sarcoplasmic Reticulum | 2 | 2003 | 42 | 0.190 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2023 | 61 | 0.190 |
Why?
| | Discrimination Learning | 1 | 2022 | 54 | 0.190 |
Why?
| | Theta Rhythm | 1 | 2022 | 18 | 0.190 |
Why?
| | Olfactory Perception | 1 | 2022 | 18 | 0.190 |
Why?
| | Sulfonamides | 5 | 2013 | 581 | 0.190 |
Why?
| | Reperfusion Injury | 1 | 2025 | 300 | 0.180 |
Why?
| | Aorta | 1 | 2025 | 430 | 0.180 |
Why?
| | Optogenetics | 1 | 2023 | 109 | 0.180 |
Why?
| | Association Learning | 1 | 2022 | 71 | 0.180 |
Why?
| | Vascular Surgical Procedures | 1 | 2025 | 340 | 0.180 |
Why?
| | Nucleus Accumbens | 2 | 2013 | 135 | 0.180 |
Why?
| | Cell Hypoxia | 2 | 2015 | 247 | 0.180 |
Why?
| | Protein Subunits | 2 | 2013 | 226 | 0.170 |
Why?
| | Embryo, Mammalian | 2 | 2015 | 232 | 0.160 |
Why?
| | Single Molecule Imaging | 2 | 2021 | 46 | 0.160 |
Why?
| | Swine | 1 | 2023 | 833 | 0.160 |
Why?
| | Animals, Newborn | 3 | 2014 | 902 | 0.160 |
Why?
| | Neurotoxins | 1 | 2020 | 28 | 0.160 |
Why?
| | Neural Inhibition | 2 | 2012 | 178 | 0.160 |
Why?
| | Spodoptera | 3 | 2009 | 40 | 0.160 |
Why?
| | Enzyme Inhibitors | 6 | 2015 | 826 | 0.150 |
Why?
| | Point Mutation | 2 | 2014 | 243 | 0.150 |
Why?
| | Protective Agents | 1 | 2019 | 42 | 0.150 |
Why?
| | Action Potentials | 2 | 2014 | 507 | 0.150 |
Why?
| | Prefrontal Cortex | 1 | 2022 | 328 | 0.150 |
Why?
| | Recombinant Fusion Proteins | 3 | 2010 | 675 | 0.150 |
Why?
| | Protein Structure, Tertiary | 2 | 2014 | 862 | 0.150 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2006 | 906 | 0.150 |
Why?
| | Nervous System | 1 | 1999 | 70 | 0.140 |
Why?
| | Purkinje Cells | 1 | 2019 | 64 | 0.140 |
Why?
| | Multigene Family | 1 | 2019 | 204 | 0.140 |
Why?
| | Mutation, Missense | 2 | 2014 | 340 | 0.140 |
Why?
| | Mutagenesis | 2 | 2011 | 192 | 0.140 |
Why?
| | Female | 8 | 2021 | 78376 | 0.140 |
Why?
| | Movement | 1 | 2020 | 294 | 0.140 |
Why?
| | RNA, Messenger | 3 | 2018 | 2832 | 0.140 |
Why?
| | Kinetics | 2 | 2011 | 1629 | 0.130 |
Why?
| | Resuscitation | 1 | 2020 | 302 | 0.130 |
Why?
| | Exons | 1 | 2018 | 358 | 0.120 |
Why?
| | Blotting, Western | 3 | 2009 | 1187 | 0.120 |
Why?
| | Membrane Potentials | 2 | 2014 | 280 | 0.120 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4569 | 0.120 |
Why?
| | Organ Culture Techniques | 1 | 2016 | 154 | 0.120 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 299 | 0.120 |
Why?
| | Proteins | 1 | 2001 | 1022 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2013 | 2032 | 0.110 |
Why?
| | Miniature Postsynaptic Potentials | 1 | 2014 | 10 | 0.110 |
Why?
| | Ubiquitin-Specific Proteases | 1 | 2014 | 4 | 0.110 |
Why?
| | COS Cells | 2 | 2006 | 181 | 0.110 |
Why?
| | I-kappa B Kinase | 1 | 2014 | 51 | 0.100 |
Why?
| | Pepstatins | 1 | 2014 | 4 | 0.100 |
Why?
| | Electrical Synapses | 1 | 2014 | 11 | 0.100 |
Why?
| | Sequestosome-1 Protein | 1 | 2014 | 15 | 0.100 |
Why?
| | Phosphoserine | 1 | 2014 | 27 | 0.100 |
Why?
| | Serum Albumin, Bovine | 1 | 2014 | 62 | 0.100 |
Why?
| | Muramidase | 1 | 2014 | 67 | 0.100 |
Why?
| | RNA Interference | 2 | 2014 | 476 | 0.100 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2014 | 68 | 0.100 |
Why?
| | Staurosporine | 1 | 2013 | 22 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 635 | 0.100 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2013 | 28 | 0.100 |
Why?
| | Pregnancy | 2 | 2018 | 7191 | 0.100 |
Why?
| | Genes, Reporter | 1 | 2014 | 276 | 0.100 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 173 | 0.100 |
Why?
| | Leucine | 1 | 2014 | 116 | 0.100 |
Why?
| | Protease Inhibitors | 1 | 2014 | 102 | 0.100 |
Why?
| | Gap Junctions | 1 | 2014 | 67 | 0.100 |
Why?
| | GTPase-Activating Proteins | 1 | 2013 | 82 | 0.100 |
Why?
| | Heat-Shock Proteins | 1 | 2014 | 138 | 0.100 |
Why?
| | Ventral Tegmental Area | 1 | 2013 | 60 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 427 | 0.100 |
Why?
| | Myosin Type I | 1 | 2012 | 1 | 0.090 |
Why?
| | Cytoplasmic Vesicles | 1 | 2012 | 14 | 0.090 |
Why?
| | Microtubule-Associated Proteins | 1 | 2014 | 196 | 0.090 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2014 | 193 | 0.090 |
Why?
| | Glucose Transporter Type 4 | 1 | 2012 | 38 | 0.090 |
Why?
| | Amphetamine-Related Disorders | 1 | 2013 | 48 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 140 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 1 | 1 | 2011 | 3 | 0.090 |
Why?
| | Cocaine | 1 | 2013 | 161 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 321 | 0.090 |
Why?
| | Base Sequence | 3 | 2002 | 2191 | 0.090 |
Why?
| | Solutions | 1 | 2011 | 167 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2185 | 0.080 |
Why?
| | Serine | 1 | 2011 | 145 | 0.080 |
Why?
| | Cognition | 1 | 2019 | 1269 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1087 | 0.080 |
Why?
| | Alanine | 1 | 2011 | 171 | 0.080 |
Why?
| | Viral Fusion Proteins | 1 | 2010 | 21 | 0.080 |
Why?
| | Gene Products, tat | 1 | 2010 | 22 | 0.080 |
Why?
| | Muscle, Skeletal | 2 | 2003 | 1796 | 0.080 |
Why?
| | Cell-Penetrating Peptides | 1 | 2010 | 20 | 0.080 |
Why?
| | PC12 Cells | 1 | 2010 | 42 | 0.080 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2010 | 45 | 0.080 |
Why?
| | Seizures | 1 | 2014 | 477 | 0.080 |
Why?
| | Patch-Clamp Techniques | 1 | 2010 | 289 | 0.070 |
Why?
| | Conditioning, Classical | 1 | 2010 | 120 | 0.070 |
Why?
| | Electric Stimulation | 1 | 2010 | 276 | 0.070 |
Why?
| | Insulin | 2 | 2012 | 2507 | 0.070 |
Why?
| | Immunohistochemistry | 5 | 2013 | 1718 | 0.070 |
Why?
| | Cell Membrane | 1 | 2012 | 706 | 0.070 |
Why?
| | Rats, Wistar | 2 | 2007 | 451 | 0.070 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1048 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 266 | 0.070 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2009 | 561 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2010 | 452 | 0.060 |
Why?
| | Behavior, Animal | 1 | 2010 | 520 | 0.060 |
Why?
| | Gene Expression | 2 | 2006 | 1490 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2006 | 4 | 0.060 |
Why?
| | Mutant Proteins | 1 | 2006 | 106 | 0.060 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 2006 | 12 | 0.060 |
Why?
| | Subcellular Fractions | 1 | 2006 | 74 | 0.060 |
Why?
| | Trinucleotide Repeats | 1 | 2006 | 31 | 0.060 |
Why?
| | Chickens | 1 | 2006 | 191 | 0.060 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2006 | 108 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 304 | 0.050 |
Why?
| | Glycine | 1 | 2006 | 187 | 0.050 |
Why?
| | Immunoblotting | 3 | 2013 | 300 | 0.050 |
Why?
| | Models, Biological | 3 | 2003 | 1822 | 0.050 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 2 | 2014 | 15 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2003 | 45 | 0.050 |
Why?
| | Neurites | 1 | 2003 | 50 | 0.050 |
Why?
| | Integrins | 1 | 2003 | 90 | 0.050 |
Why?
| | Actinin | 1 | 2002 | 12 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 292 | 0.040 |
Why?
| | Immunoprecipitation | 2 | 2014 | 151 | 0.040 |
Why?
| | Odorants | 1 | 2022 | 116 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2002 | 541 | 0.040 |
Why?
| | Islets of Langerhans | 1 | 2007 | 833 | 0.040 |
Why?
| | Recovery of Function | 1 | 2025 | 710 | 0.040 |
Why?
| | Stroke | 1 | 2010 | 1258 | 0.040 |
Why?
| | Motor Activity | 1 | 2025 | 722 | 0.040 |
Why?
| | Kidney | 2 | 2006 | 1496 | 0.040 |
Why?
| | Cytoskeleton | 1 | 2001 | 195 | 0.040 |
Why?
| | Ganglia | 1 | 1999 | 18 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2007 | 978 | 0.040 |
Why?
| | Enzyme Induction | 1 | 1999 | 88 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1786 | 0.040 |
Why?
| | Microsomes | 1 | 1998 | 33 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1998 | 54 | 0.040 |
Why?
| | Organ Specificity | 1 | 1999 | 313 | 0.040 |
Why?
| | Enzymes, Immobilized | 1 | 1998 | 30 | 0.030 |
Why?
| | Apoptosis | 1 | 2007 | 2430 | 0.030 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2018 | 64 | 0.030 |
Why?
| | Head | 1 | 1999 | 120 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2019 | 252 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 418 | 0.030 |
Why?
| | Microscopy, Immunoelectron | 1 | 2016 | 43 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 2017 | 415 | 0.030 |
Why?
| | Pseudopodia | 1 | 2016 | 27 | 0.030 |
Why?
| | Microscopy, Confocal | 2 | 2010 | 321 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 214 | 0.030 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2017 | 178 | 0.030 |
Why?
| | Sarcomeres | 1 | 1996 | 98 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1996 | 277 | 0.030 |
Why?
| | DNA Primers | 1 | 1996 | 512 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2014 | 25 | 0.030 |
Why?
| | Kainic Acid | 1 | 2014 | 33 | 0.030 |
Why?
| | Deubiquitinating Enzyme CYLD | 1 | 2014 | 3 | 0.030 |
Why?
| | Polyubiquitin | 1 | 2014 | 8 | 0.030 |
Why?
| | Ion Transport | 1 | 2014 | 63 | 0.030 |
Why?
| | Muscle Proteins | 1 | 1996 | 244 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 83 | 0.030 |
Why?
| | Synaptic Membranes | 1 | 2013 | 16 | 0.030 |
Why?
| | Cell Fractionation | 2 | 2003 | 52 | 0.020 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2013 | 59 | 0.020 |
Why?
| | Polyribosomes | 1 | 2013 | 22 | 0.020 |
Why?
| | Conditioning, Operant | 1 | 2013 | 99 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2014 | 159 | 0.020 |
Why?
| | Calcium Channels, L-Type | 1 | 2014 | 118 | 0.020 |
Why?
| | Amphetamine | 1 | 2013 | 38 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 1996 | 1253 | 0.020 |
Why?
| | Rats, Long-Evans | 1 | 2013 | 125 | 0.020 |
Why?
| | Potassium | 1 | 2013 | 152 | 0.020 |
Why?
| | Time Factors | 3 | 2013 | 7183 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 311 | 0.020 |
Why?
| | Exocytosis | 1 | 2012 | 84 | 0.020 |
Why?
| | Dendrites | 1 | 2013 | 106 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2013 | 220 | 0.020 |
Why?
| | Cytosol | 1 | 2012 | 227 | 0.020 |
Why?
| | Neural Pathways | 1 | 2013 | 311 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 401 | 0.020 |
Why?
| | Lysine | 1 | 2014 | 302 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 783 | 0.020 |
Why?
| | Endocytosis | 1 | 2012 | 168 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 336 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1258 | 0.020 |
Why?
| | Central Nervous System Stimulants | 1 | 2013 | 185 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 852 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 451 | 0.020 |
Why?
| | Adrenergic alpha-1 Receptor Agonists | 1 | 2010 | 3 | 0.020 |
Why?
| | Liver | 1 | 1999 | 1888 | 0.020 |
Why?
| | Phenylephrine | 1 | 2010 | 75 | 0.020 |
Why?
| | Calcineurin | 1 | 2010 | 105 | 0.020 |
Why?
| | Receptors, GABA-A | 1 | 2010 | 138 | 0.020 |
Why?
| | Thapsigargin | 1 | 2007 | 20 | 0.020 |
Why?
| | Androgen Receptor Antagonists | 1 | 2007 | 35 | 0.020 |
Why?
| | Androstadienes | 1 | 2007 | 76 | 0.020 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 54 | 0.020 |
Why?
| | Luciferases | 1 | 2007 | 152 | 0.020 |
Why?
| | Prostate-Specific Antigen | 1 | 2007 | 162 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 781 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 139 | 0.010 |
Why?
| | Receptors, Androgen | 1 | 2007 | 153 | 0.010 |
Why?
| | Androgens | 1 | 2007 | 186 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2007 | 919 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 983 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 381 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2007 | 437 | 0.010 |
Why?
| | Doxorubicin | 1 | 2007 | 397 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 1048 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2003 | 93 | 0.010 |
Why?
| | Isoquinolines | 1 | 2003 | 44 | 0.010 |
Why?
| | Organisms, Genetically Modified | 1 | 2003 | 15 | 0.010 |
Why?
| | Fibronectins | 1 | 2003 | 136 | 0.010 |
Why?
| | ras Proteins | 1 | 2003 | 151 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2499 | 0.010 |
Why?
| | Luminescent Proteins | 1 | 2003 | 185 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2007 | 847 | 0.010 |
Why?
| | HeLa Cells | 1 | 2003 | 650 | 0.010 |
Why?
| | Cell Movement | 1 | 2003 | 965 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2003 | 962 | 0.010 |
Why?
|
|
Bayer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|